HC Wainwright Has Pessimistic Opinion of NAGE Q1 Earnings

Niagen Bioscience, Inc. (NASDAQ:NAGE) – Equities researchers at HC Wainwright lowered their Q1 2027 earnings estimates for shares of Niagen Bioscience in a research note issued on Wednesday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.03. The consensus estimate for Niagen Bioscience’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Niagen Bioscience’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.02 EPS and Q4 2027 earnings at $0.03 EPS.

Several other research firms also recently commented on NAGE. Roth Capital restated a “buy” rating on shares of Niagen Bioscience in a report on Wednesday, August 5th. Canaccord Genuity Group decreased their target price on Niagen Bioscience from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Friday, October 30th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Niagen Bioscience in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Niagen Bioscience currently has an average rating of “Buy” and a consensus price target of $10.00.

Niagen Bioscience Stock Performance

Shares of NASDAQ NAGE opened at $2.52 on Thursday. The firm has a market capitalization of $200.70 million, a price-to-earnings ratio of 14.00 and a beta of 2.12. The stock has a 50 day moving average price of $2.81 and a 200 day moving average price of $3.87. Niagen Bioscience has a 52-week low of $2.31 and a 52-week high of $7.95.

Niagen Bioscience (NASDAQ:NAGE) last issued its earnings results on Wednesday, November 4th. The company reported ($0.01) EPS for the quarter, hitting analysts’ consensus estimates of ($0.01). Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The business had revenue of $27.19 million for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC lifted its position in shares of Niagen Bioscience by 81.5% in the 3rd quarter. Kestra Advisory Services LLC now owns 24,500 shares of the company’s stock worth $72,000 after purchasing an additional 11,000 shares during the period. State of Wyoming boosted its stake in shares of Niagen Bioscience by 327.0% during the third quarter. State of Wyoming now owns 63,108 shares of the company’s stock valued at $184,000 after purchasing an additional 48,329 shares in the last quarter. Abel Hall LLC bought a new position in shares of Niagen Bioscience during the third quarter valued at approximately $99,000. SteelPeak Wealth LLC increased its holdings in Niagen Bioscience by 2.2% during the third quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company’s stock valued at $10,446,000 after buying an additional 77,306 shares during the period. Finally, Tidal Investments LLC purchased a new position in Niagen Bioscience during the second quarter valued at approximately $394,000. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About Niagen Bioscience

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.